HomeClinical Trials, Studies, Data UpdatesNew Study Shows Consistent Medical-Grade Accuracy and Environmental Benefits to Replacing Mercury Sphygmomanometers with OMRON HEM-907XL

New Study Shows Consistent Medical-Grade Accuracy and Environmental Benefits to Replacing Mercury Sphygmomanometers with OMRON HEM-907XL

A peer-reviewed, published study by the National Center for Health Statistics and supported by the CDC comparing manual and electronic blood pressure monitors demonstrated that medical professionals could replace the mercury sphygmomanometer traditionally used in physician offices with an automated monitor such as the OMRON HEM-907XL and maintain consistent medical-grade accuracy. Researchers found the OMRON HEM-907XL matched the accuracy of mercury sphygmomanometers and concluded that making the switch to the automated blood pressure monitor could reduce and eliminate the presence of mercury in blood pressure monitors, and achieve environmental benefits and cost effectiveness for medical practices.

“OMRON blood pressure monitors are reviewed by the FDA, cleared as medical devices, and rank as the number one brand among physicians and pharmacists. This new study is a testament to the accuracy and reliability of our medical devices,” said Jim Li, executive director, Global Medical Affairs for OMRON Healthcare. “This study highlights the opportunity for medical professionals and benefits the environment by replacing the mercury sphygmomanometer.”

The test group was comprised of 4,477 eligible participants over a one-year period with ages ranging from 18 through 60 and over. Within the test group, blood pressure was measured using two protocols – the auscultation protocol (AP) administered by a physician using a mercury sphygmomanometer and the oscillometric protocol (OP) administered by a health technician using an OMRON HEM-907XL device – in a randomly assigned order. Between-protocol, mean systolic BP and diastolic BP measurements were compared. Then, the prevalence of stage 1 high blood pressure was determined, and protocols were evaluated.

Results showed that although mean systolic BP and diastolic BP obtained by AP and OP differed, the prevalence of stage 1 high blood pressure did not differ, suggesting that a change in protocol may not affect blood pressure prevalence estimates.
This research adds to a body of established science on OMRON’s HEM-907XL, which is clinically validated for accuracy and designed for use in a professional setting including a physician’s office, hospital, or other point of care environment. For more information on OMRON’s HEM-907XL or Professional Intellisense® Blood Pressure Monitor, visit www.omronhealthcare.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy